中国医药
中國醫藥
중국의약
CHINA MEDICINE
2011年
8期
978-980
,共3页
魏兵%李奇玉%蒋静%李薇
魏兵%李奇玉%蔣靜%李薇
위병%리기옥%장정%리미
支原体肺炎%氨溴特罗%儿童
支原體肺炎%氨溴特囉%兒童
지원체폐염%안추특라%인동
Mycoplasma pneumonia%Ambroxol hydrochloride and clenbuterol hydrochloride%Children
目的 观察氨溴特罗口服液治疗肺炎支原体肺炎的临床疗效.方法 106例哮喘患儿随机分为观察组52例和对照组54例,在静脉滴注红霉素的基础上观察组给予氨溴特罗口服液,对照组给予盐酸氨溴索糖浆.结果 观察组痊愈12例,有效16例,无效6例,总有效率88.5%(46例),对照组痊愈9例,显效17例,有效17例,总有效率79.6%(43例).观察组总有效率明显高于对照组,差异有统计学意义(X2=3.41,P＜0.01).观察组咳嗽、啰音消失时间、低氧血症纠正时间及住院天数较对照组明显缩短[分别为(10.3±3.6)d比(15.8±4.6)d、(3.8±1.9)d比(5.2±2.1)d、(2.5±0.7)d比(3.9±0.9)d、(10.8±4.8)d比(14.5±4.8)d,均P＜0.01].观察组治疗后较治疗前用力肺活量、第1秒用力呼气量、呼气流量峰值、25%肺活量最大呼气流量和50%肺活量最大呼气流量明显改善,气道反应性明显减轻,差异均有统计学意义(P＜0.01).结论 氨溴特罗口服液能有效控制症状,降低气道高反应性,改善肺功能.
目的 觀察氨溴特囉口服液治療肺炎支原體肺炎的臨床療效.方法 106例哮喘患兒隨機分為觀察組52例和對照組54例,在靜脈滴註紅黴素的基礎上觀察組給予氨溴特囉口服液,對照組給予鹽痠氨溴索糖漿.結果 觀察組痊愈12例,有效16例,無效6例,總有效率88.5%(46例),對照組痊愈9例,顯效17例,有效17例,總有效率79.6%(43例).觀察組總有效率明顯高于對照組,差異有統計學意義(X2=3.41,P＜0.01).觀察組咳嗽、啰音消失時間、低氧血癥糾正時間及住院天數較對照組明顯縮短[分彆為(10.3±3.6)d比(15.8±4.6)d、(3.8±1.9)d比(5.2±2.1)d、(2.5±0.7)d比(3.9±0.9)d、(10.8±4.8)d比(14.5±4.8)d,均P＜0.01].觀察組治療後較治療前用力肺活量、第1秒用力呼氣量、呼氣流量峰值、25%肺活量最大呼氣流量和50%肺活量最大呼氣流量明顯改善,氣道反應性明顯減輕,差異均有統計學意義(P＜0.01).結論 氨溴特囉口服液能有效控製癥狀,降低氣道高反應性,改善肺功能.
목적 관찰안추특라구복액치료폐염지원체폐염적림상료효.방법 106례효천환인수궤분위관찰조52례화대조조54례,재정맥적주홍매소적기출상관찰조급여안추특라구복액,대조조급여염산안추색당장.결과 관찰조전유12례,유효16례,무효6례,총유효솔88.5%(46례),대조조전유9례,현효17례,유효17례,총유효솔79.6%(43례).관찰조총유효솔명현고우대조조,차이유통계학의의(X2=3.41,P＜0.01).관찰조해수、라음소실시간、저양혈증규정시간급주원천수교대조조명현축단[분별위(10.3±3.6)d비(15.8±4.6)d、(3.8±1.9)d비(5.2±2.1)d、(2.5±0.7)d비(3.9±0.9)d、(10.8±4.8)d비(14.5±4.8)d,균P＜0.01].관찰조치료후교치료전용력폐활량、제1초용력호기량、호기류량봉치、25%폐활량최대호기류량화50%폐활량최대호기류량명현개선,기도반응성명현감경,차이균유통계학의의(P＜0.01).결론 안추특라구복액능유효공제증상,강저기도고반응성,개선폐공능.
Objective To discuss the clinical efficacy of ambroxol hydrochloride and clenbuterol hydrochloride oral solution for children with mycoplasma pneumonia. Methods Totally 106 cases of children with mycoplasma pneumonia were randomly divided into observation group and control group. Based on erythromycin, the observation group used ambroxol hydrochloride and clenbuterol hydrochloride oral solution and the control group used the ambroxol. Results The total efficacy of observation group was higher than that of control group. Cough, rales disappearance time, hypoxemia recovery time and length of hospital stay in observation group were significantly shorter than those in the control group[(10.3±3.6)d vs (15.8±4.6)d, (3.8±1.9)d vs (5.2±2.1)d, (2.5±0.7)d vs (3.9±0.9)d,(10. 8 ±4.8)d vs (14.5 ±4. 8)d, P＜0.01]. Pulmonary function parameters of forced vital capacity, forced expiratory volume in first second, peak expiratory flow, maximal expiratory flow in 25% vital capacity (MEF25)and MEF50 were significantly decreased in observation group compared with control group (P＜0. 01). Conclusion Ambroxol hydrochloride and clenbuterol hydrochloride oral solution can effectively control the symptoms, decrease degrade airway hyperresponsiveness and improve lung function.
